While the facility has had several run-ins in recent years with U.S. regulators, selling the site is part of Lilly’s broader global manufacturing strategy.
The Bloomington, Indiana facility is a fill-finish site for Regeneron’s Eylea HD and odronextamab and handles the final stages of drug preparation and packaging.
The agreement includes a 15% tariff on branded pharmaceutical products imported from the European Union to the United States, elevating costs across the pharma value chain.
Having an effective strategy so products remain free from contaminants is essential to pharmaceutical manufacturing to prevent delays, product recalls, and patient harm.
The South Korean manufacturer and exporter of biosimilars said it has been designated as the preferred bidder on a large-scale cGMP drug substance facility.
While the drugmaker provided few details on the plan, a new restructuring program is meant to align its global manufacturing to reflect changes in the business.
Although some analysts do not expect it to have a significant financial impact, others project tariffs could increase industry costs by $13 billion to $19 billion per year.
President Donald Trump and European Commission President Ursula von der Leyen appear to differ on how their trade agreement addresses pharma-specific tariffs.
With the looming threat of Trump’s tariffs on pharmaceuticals, major drugmakers continue to invest billions of dollars in domestic manufacturing in the United States.
Marc Casper says the Ridgefield site, which specializes in fill‑finish and packaging of aseptic injectable medications, aligns with its plans to bolster U.S. capacity.
The company saw positive momentum in mammalian, bioconjugates, and small molecules, offsetting lower sales from its cell and gene therapy and microbial businesses.
CEO Pascal Soriot said the company’s capital expenditure will support its goal of reaching $80 billion in revenue by 2030, with 50% generated in the United States.
This week’s announcement about a new multibillion-dollar investment in PCI Pharma Services is good news for contract development and manufacturing organizations.
CEO Joaquin Duato told investors on Wednesday’s earnings call that the provisions of the law have “enabled” Johnson & Johnson’s commitment to invest $55 billion in the U.S.
Peter DeYoung, CEO of Piramal Global Pharma, says the geopolitical situation and trend toward onshoring “happens to be synergistic” with its investment in the United States.
A new survey from Unispace Life Sciences finds 57% of senior executives see the adoption of intelligent systems as critical to the next generation of laboratory environments.
Out of 202 Complete Response Letters issued between 2020 and 2024, 150 involved quality/manufacturing issues, according to the regulator’s newly released documents.
Drug manufacturers have been left in a climate of anxious anticipation and a heightened state of uncertainty as the pharma industry waits to see if the president is bluffing.
Generics, which make up approximately 90% of prescription volume in the U.S., are produced primarily in India as Hikma looks to onshore production of these critical drugs.
The tariffs on pharmaceuticals would have a grace period of up to a year and a half to give drugmakers the opportunity to move their manufacturing operations to the U.S.
After touring the Fishers facility, William Blair analysts say demand for syringes is “healthy and robust” with a sequential utilization ramp-up expected in coming quarters.
Alessandro Maselli, who took the helm in 2022, has navigated the global CDMO through the COVID-19 pandemic and the landmark $16.5 billion acquisition by Novo Holdings.
In the pharmaceutical, biotech, and life sciences industries, the terms validation and commissioning are frequently — and mistakenly — used interchangeably.
While jobs dropped 3.7% last year, the state is still home to the largest number of manufacturing-related life science jobs in the U.S., according to Biocom California.
Pharmaceutical manufacturers often accept avoidable limitations of ULT freezers, such as temperature fluctuations, large footprints, and reactive maintenance. They should be demanding...
The strategic realignment is aimed at better serving customers across the drug development lifecycle, from research and discovery to clinical and commercial manufacturing.
